04/23/13
Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement
 
11/08/12
The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
 
05/29/12
Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
 
05/18/12
Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
Posters: EASL | DDW